• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    2/9/22 2:38:49 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NTLA alert in real time by email
    SC 13G/A 1 tm225659d34_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 4)*

     

    Intellia Therapeutics, Inc.

    (Name of Issuer)

     

    Common stock

    (Title of Class of Securities)

     

    45826J105

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 45826J105 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS  
    ARK Investment Management LLC  
     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
    (a)¨  
    (b)¨  
    3. SEC USE ONLY  
       
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
    Delaware, United States  
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER  
     6,809,880      
     
    6. SHARED VOTING POWER  
    805,490  
     
    7. SOLE DISPOSITIVE POWER  
     7,916,882  
     
    8. SHARED DISPOSITIVE POWER  
    0  
     
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
     7,916,882  
     
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
    ☐  
     
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
    10.64%  
     
    12. TYPE OF REPORTING PERSON  
    IA  
     

     

     

     

     

    CUSIP No. 45826J105 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:

     

    Intellia Therapeutics, Inc.

     

    Item 1(b) Address of issuer's principal executive offices:

     

    40 Erie Street, Suite 130,

    Cambridge, MA 02139

     

    Item 2(a) Name of person filing:

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    3 East 28th Street, 7th Floor 

    New York, NY 10016

     

    Item 2(c) Citizenship:

     

    Delaware, United States

     

    Item 2(d) Title of class of securities:

     

    Common stock

     

    Item 2(e) CUSIP No.:

     

    45826J105

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    CUSIP No. 45826J105 13G Page 4 of 5 Pages 

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership

     

    (a)          Amount beneficially owned:

     

    7,916,882

     

    (b)          Percent of class:

     

    10.64%

     

    (c)          Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote:  6,809,880

     

    (ii) Shared power to vote or to direct the vote:  805,490

     

    (iii) Sole power to dispose or to direct the disposition of:  7,916,882

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 45826J105 13G Page 5 of 5 Pages 

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    February 9, 2022

     

      ARK Investment Management LLC  
         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title:    Chief Compliance Officer

     

     

     

    Get the next $NTLA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTLA

    DatePrice TargetRatingAnalyst
    11/12/2025Outperform → Peer Perform
    Wolfe Research
    11/11/2025$8.00Outperform → In-line
    Evercore ISI
    11/7/2025$5.00Neutral → Underweight
    Analyst
    10/28/2025$14.00Outperform → Sector Perform
    RBC Capital Mkts
    10/28/2025Outperform → Mkt Perform
    Bernstein
    10/27/2025Outperform → Mkt Perform
    William Blair
    10/27/2025Buy → Neutral
    Guggenheim
    10/6/2025$33.00Mkt Perform → Mkt Outperform
    Citizens JMP
    More analyst ratings

    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intellia Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Intellia Therapeutics from Outperform to Peer Perform

    11/12/25 8:54:37 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Intellia Therapeutics from Outperform to In-line and set a new price target of $8.00

    11/11/25 8:02:05 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics downgraded by Analyst with a new price target

    Analyst downgraded Intellia Therapeutics from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:28:27 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Scientific Officer Schultes Birgit C sold $539 worth of shares (31 units at $17.38), decreasing direct ownership by 0.03% to 105,184 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    10/3/25 5:13:56 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VP, Chief Accounting Officer Dube Michael P sold $32,518 worth of shares (1,871 units at $17.38), decreasing direct ownership by 3% to 55,266 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    10/3/25 5:13:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

    One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baselineLonger-term safety data consistent with previously reported Phase 1 data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive follow-up data from the ongoing Phase 1 clinical trial of its investigational product nexiguran ziclumeran (nex-z)

    11/10/25 3:17:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

    Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for at least seven months (up to 32 months)Among the 11 patients who originally received a 50 mg dose in Phase 2, 10 were attack-free and LTP-free Continue to observe a well-tolerated safety profile with up to three years of patient follow-up and no new long-term risks identified CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi

    11/8/25 5:13:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

    Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo-z on November 8 at ACAAI 2025Ended third quarter with approximately $670 million in cash, cash equivalents and marketable securities; expected to fund operations into mid-2027 Conference call today a

    11/6/25 4:00:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.

    SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)

    11/12/25 3:55:19 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.

    SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)

    11/12/25 1:47:50 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

    11/10/25 5:24:38 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Leadership Updates

    Live Leadership Updates

    View All

    Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

    Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

    11/16/24 10:16:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

    Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do

    10/24/24 8:01:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

    - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A

    10/10/24 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Financials

    Live finance-specific insights

    View All

    Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

    Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo-z on November 8 at ACAAI 2025Ended third quarter with approximately $670 million in cash, cash equivalents and marketable securities; expected to fund operations into mid-2027 Conference call today a

    11/6/25 4:00:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

    CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively. This action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial's protoco

    10/27/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-endExpanding total enrollment of the MAGNITUDE study to approximately 1,200 patients, subject to health authority review, with no expected impact on previous projected enrollment or financial runwayExpect to complete enrollment by first half 2026 in the global Phase 3 MAGNITUDE-2 study evaluating nex-z in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Expect to complete randomization in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) in heredita

    8/7/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    2/13/24 5:07:59 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    1/29/24 4:00:59 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

    SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)

    1/24/24 11:21:06 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care